多发性骨髓瘤中基因重排导致激酶结构域激活
研究分析958例骨髓瘤患者共1421份样本,靶向检测发现1.5%患者存在融合基因,多数为亚克隆性,累及受体酪氨酸激酶和胞质激酶,可激活MEK/ERK、NF-κB或炎症信号通路;1例EML4-ALK融合为克隆性,提示驱动疾病发病。
要点
- 958例患者1421份样本中,1.5%患者检出融合基因。
- 融合基因累及受体酪氨酸激酶(ALK、ROS1、NTRK3、FGFR1)和胞质激酶(BRAF、MAP3K14、MAPK14)。
- 多数融合基因为亚克隆性,1例EML4-ALK融合为克隆性,提示驱动疾病发病。
核心结论
- 多发性骨髓瘤中存在基因重排导致的激酶激活,为使用其他癌症中已有的治疗提供机会。
研究设计与样本
- 分析958例骨髓瘤患者共1421份样本,使用靶向检测方法。
主要发现
- 1.5%的患者检出融合基因,融合基因均为框内融合。
- 多数融合基因包含受体酪氨酸激酶(ALK、ROS1、NTRK3、FGFR1)或胞质激酶(BRAF、MAP3K14、MAPK14)的激酶结构域,可激活MEK/ERK、NF-κB或炎症信号通路。
- 融合基因存在于冒烟型骨髓瘤、新诊断骨髓瘤和复发患者样本中,表明并非仅为晚期事件。
- 多数融合基因为亚克隆性,但1例EML4-ALK融合为克隆性,提示驱动疾病发病。
- 受体酪氨酸激酶融合的样本未同时发现克隆性Ras/Raf突变,提示MEK/ERK通路激活的平行机制。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chromosomal rearrangements that result in oncogenic kinase activation are present in many solid and hematological malignancies, but none have been reported in multiple myeloma (MM). Here we analyzed 1421 samples from 958 myeloma patients using a targeted assay and detected fusion genes in 1.5% of patients. These fusion genes were in-frame and the majority of them contained kinase domains from either receptor tyrosine kinases (ALK, ROS1, NTRK3, and FGFR1) or cytoplasmic kinases (BRAF, MAP3K14, and MAPK14), which would result in the activation of MEK/ERK, NF-κB, or inflammatory signaling pathways. Fusion genes were present in smoldering MM, newly diagnosed MM, and relapse patient samples indicating they are not solely late events. Most fusion genes were subclonal in nature, but one EML4-ALK fusion was clonal indicating it is a driver of disease pathogenesis. Samples with fusions of receptor tyrosine kinases were not found in conjunction with clonal Ras/Raf mutations indicating a parallel mechanism of MEK/ERK pathway activation. Fusion genes involving MAP3K14 (NIK), which regulates the NF-κB pathway, were detected as were t(14;17) rearrangements involving NIK in 2% of MM samples. Activation of kinases in myeloma through rearrangements presents an opportunity to use treatments existing in other cancers.
引用
- Morgan GJ, He J, Tytarenko R, et al. Kinase domain activation through gene rearrangement in multiple myeloma. Leukemia. 2018. PMID: 29654269. doi:10.1038/s41375-018-0108-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。